Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) Director Nathaniel E. David unloaded 1,505 shares of the stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $33.08, for a total transaction of $49,785.40. Following the transaction, the director now directly owns 491,167 shares of the company’s stock, valued at approximately $16,247,804. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded up 4.92% during mid-day trading on Monday, hitting $34.53. The stock had a trading volume of 168,391 shares. KYTHERA Biopharmaceuticals has a 52-week low of $23.03 and a 52-week high of $56.36. The stock has a 50-day moving average of $35.79 and a 200-day moving average of $39.06. The company’s market cap is $782.3 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last released its earnings data on Thursday, May 8th. The company reported ($3.18) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.67) by $2.51. Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Receive News & Ratings for KYTHERA Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KYTHERA Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.